{
  "@context": "https://orbyd.app/schemas/dossier.v1.json",
  "ticker": "IVA",
  "name": "Inventiva S.A.",
  "url": "https://orbyd.app/dossiers/IVA/",
  "json_url": "https://orbyd.app/dossiers/IVA.json",
  "status": "DORMANT",
  "current_conviction": "LOW",
  "archetype": {
    "code": "a5",
    "n": 5
  },
  "current_thesis": "Single-asset MASH binary: lanifibranor's NATiV3 Phase 3 topline (Q4 2026) is the whole equity. The June 2 refinancing cleared the funding overhang (runway into early Q1 2028) and Cantor initiated Overweight July 17. Stock coils on the $4.40 offering price a positioning setup ahead of a dated binary, not an accelerating tape.",
  "invalidation_trigger": "A weekly close below $4.40 puts the June equity offering underwater and breaks the structural floor, opening the $2.85 52-week low; a NATiV3 readout slip into 2027 would compound it by re-opening funding risk.",
  "catalyst_date": null,
  "outcome": "OPEN",
  "outcome_date": null,
  "invalidation_fired": null,
  "themes": [
    "binary-catalyst-biotech",
    "precision-biotech-therapeutics",
    "oncology-immunology"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "NATiV3 Phase 3 topline is the binary guided Q4 2026, undated; ~1,000 pts F2-F3, 72-week histology, enrollment completed 2026-04-01. Treat as an earnings-grade blackout: avoid fresh size into an unconfirmed readout date.",
    "$4.40 is the June 2, 2026 equity-offering clearing price (27.3M new ADS, ~$110.8M net) structural reference floor and the level to grade.",
    "Funded into early Q1 2028 after the June refinancing (EIB ~€63M repaid, €50M warrant buyback, up to €130M debt at 8.90-9.90%). Runway assumes full optional-warrant exercise fragile if the readout slips.",
    "Competitive bar: Rezdiffra (approved Mar 2024) and semaglutide MASH label (Aug 2025) are already commercial; lanifibranor must differentiate on fibrosis.",
    "Consensus Strong Buy, avg PT ~$15.13 (13 analysts), range $8.80-$26; Cantor Fitzgerald Overweight initiation 2026-07-17."
  ],
  "body_markdown": "## Current Thesis\nSingle-asset MASH binary. Lanifibranor's NATiV3 Phase 3 topline (expected Q4 2026) is effectively the entire equity value. The June 2, 2026 capital-structure overhaul removed the financing overhang that had capped the tape, and Cantor Fitzgerald initiated Overweight on July 17, 2026. The stock coils near the $4.40 June offering price into a de-risked-funding, pre-readout window a positioning name ahead of a dated binary, with no momentum signature yet.\n\n## Bull Case\n- Lanifibranor is an oral pan-PPAR (α/δ/γ) agonist acting on steatosis, inflammation and fibrosis through all three isoforms the only late-stage pan-PPAR in MASH. Phase 2b NATIVE hit both resolution and fibrosis endpoints (NEJM, 2021), the mechanistic basis for the Phase 3.\n- NATiV3 completed enrollment April 1, 2025 (~1,000 patients, F2–F3 advanced fibrosis, 72-week histology); topline is guided to Q4 2026. A positive dual-endpoint result in the advanced-fibrosis population re-rates a sub-$300M enterprise value toward the $8.80–$26 analyst target band (consensus ~$15.13 across 13 analysts, Strong Buy).\n- Financing overhang cleared June 2, 2026: $120M equity offering at $4.40/ADS (27,272,727 new ADSs, ~$110.8M net) plus up to €130M committed debt; the ~€63M EIB loan is repaid and €50M of EIB warrants bought back. Runway now extends into early Q1 2028 funded through the readout with no forced pre-catalyst raise.\n- Sell-side is positioning ahead of the print: Cantor Fitzgerald initiated Overweight July 17, 2026; consensus sits at Strong Buy. Analysts front-run readouts, and this initiation fits that pattern three-plus months early.\n- Market validated: Madrigal's Rezdiffra (FDA March 2024) and Novo's semaglutide MASH label (August 2025) prove MASH is a reimbursed, commercial market a differentiated fibrosis mechanism has a defensible lane.\n\n## Bear Case\n- One asset, one readout: a NATiV3 miss or ambiguous fibrosis result is a 60–80% overnight gap with no pipeline cushion. This is binary risk in its purest form.\n- The competitive bar hardened while IVA was still enrolling. Rezdiffra: resolution 26–30% vs 10% placebo, fibrosis improvement 24–26% vs 14% (MAESTRO-NASH). Semaglutide: ~63% steatohepatitis resolution vs 34% placebo at 72 weeks. Lanifibranor now reads out into a field that includes GLP-1 crossover.\n- Dilution and leverage stack up: 27.3M new ADSs just printed at $4.40; The convertible/warrant structure caps upside and adds refinancing risk if timing slips.\n- Price structure is dead. At ~$4.51 (July 24, 2026) the stock sits in the lower third of its $2.85–$7.98 52-week range, right at the June offering price. There is no accelerating tape to ride; every dollar of upside is event-gated and months away.\n- Timing has already drifted (earlier framings pointed to H2 2025/2026). A slip into 2027 stresses the runway arithmetic, which itself assumes full exercise of the optional warrant tranches.\n\n## Setup & Price Structure\n- Last ~$4.51 (July 24, 2026); 52-week range $2.85–$7.98. Trades essentially on top of the $4.40 June 2 equity-offering clearing price, which now functions as the structural reference floor the marginal institutional buyer's basis.\n- No momentum signature: dormant, range-bound, event-gated. A momentum book has nothing to chase here until either the readout window approaches or the stock reclaims mid-range ($5.50–$6.00) on expanding volume.\n- Above $4.40 the structure reads neutral-to-constructive as the funding overhang unwinds. A weekly close back below $4.40 puts the June placement underwater and re-opens the $2.85 low.\n\n## Catalyst Calendar (next 30 days)\n- NATiV3 Phase 3 topline expected Q4 2026 (~est., undated). The binary. Sits beyond the 30-day window but dominates every other input into the name.\n- H1 2026 half-year financial report typically ~September 2026 (est.); watch for runway reaffirmation into early Q1 2028 and any update to readout timing.\n- No dated, tradeable catalyst inside the next 30 days. The near term is a waiting game into the Q4 event.\n\n## What Would Change Our Mind\n- A confirmed NATiV3 topline date narrows the binary and opens a defined positioning window into the print.\n- A weekly close below $4.40 breaks the offering floor and puts the June placement underwater, opening the path to $2.85.\n- A reclaim of $5.50–$6.00 on expanding volume signals the tape starting to price a positive readout the point a momentum entry becomes valid.\n- A competitor fibrosis-specific readout (rival pan-PPAR or FGF21 asset) landing before Q4 that undercuts lanifibranor's differentiation.\n- A readout slip into 2027 stresses the runway, likely forces another raise, and invalidates the de-risked-funding leg entirely.\n\n## Correlation Notes\n- Behaves as an idiosyncratic single-asset biotech binary: low beta to SPY and the semis complex, correlated instead to MASH/liver-disease sentiment (MDGL Madrigal, VKTX Viking, AKRO Akero) and broad biotech risk appetite (XBI).\n- Not a theme-cluster momentum vehicle. A Madrigal or Akero fibrosis-data event can move IVA sympathetically, but the NATiV3 print itself is orthogonal to the rest of the tape.\n- Dual-listed (Euronext Paris IVAA / Nasdaq IVA ADS) EUR/USD and Paris-session gaps can dislocate the ADS open.",
  "first_seen": "2026-07-23",
  "last_analyzed": "2026-07-25T07:14:22+00:00",
  "last_update_source": "watchlist_research",
  "license": "Content © orbyd. Cite the canonical URL."
}